Log in

Relevant bibliographies by topics / Acute exacerbation of interstitial lung diseases / Journal articles

To see the other types of publications on this topic, follow the link: Acute exacerbation of interstitial lung diseases.

Journal articles on the topic 'Acute exacerbation of interstitial lung diseases'

Author: Grafiati

Published: 21 September 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Acute exacerbation of interstitial lung diseases.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Aritonang, Rachel S., Fanny Fachrucha, Mia Elhidsi, and Ginanjar Arum Desianti. "Oxygen Therapy in Exacerbation of Interstitial Lung Disease." Respiratory Science 4, no. 3 (2024): 221–31. http://dx.doi.org/10.36497/respirsci.v4i3.129.

Full text

Abstract:

Interstitial lung diseases (ILD) are a group of diseases that involve damage in the interstitial tissue, causing diffusion disorders which ultimately lead to hypoxemia. One of the conditions that aggravate hypoxemia in ILD patients is acute exacerbation. Acute exacerbation is a condition of deterioration of ILD that can occur in less than 1 month. During an acute exacerbation, there will be a worsening of the HRCT pattern with increased ground glass opacities and a worsening of the clinical picture including hypoxemia. Acute exacerbations are closely related to increased mortality rates. Oxyge

APA, Harvard, Vancouver, ISO, and other styles

2

Kolb, Martin, Benjamin Bondue, Alberto Pesci, et al. "Acute exacerbations of progressive-fibrosing interstitial lung diseases." European Respiratory Review 27, no. 150 (2018): 180071. http://dx.doi.org/10.1183/16000617.0071-2018.

Full text

Abstract:

Acute exacerbation of interstitial lung disease (ILD) is associated with a poor prognosis and high mortality. Numerous studies have documented acute exacerbation in idiopathic pulmonary fibrosis (IPF), but less is known about these events in other ILDs that may present a progressive-fibrosing phenotype. We propose defining acute exacerbation as an acute, clinically significant respiratory deterioration, typically less than 1 month in duration, together with computerised tomography imaging showing new bilateral glass opacity and/or consolidation superimposed on a background pattern consistent w

APA, Harvard, Vancouver, ISO, and other styles

3

Abo Elwafa, GihanS, NaglaaB Ahmed, AmanyA Abou Zeid, and MaiA Abo Elhasab. "Noninvasive ventilation in acute exacerbation of interstitial lung diseases." Egyptian Journal of Chest Diseases and Tuberculosis 72, no. 1 (2023): 99. http://dx.doi.org/10.4103/ecdt.ecdt_40_22.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Drakopanagiotakis, Fotios, Philipp Markart, and Paschalis Steiropoulos. "Acute Exacerbations of Interstitial Lung Diseases: Focus on Biomarkers." International Journal of Molecular Sciences 24, no. 12 (2023): 10196. http://dx.doi.org/10.3390/ijms241210196.

Full text

Abstract:

Interstitial lung diseases (ILDs) are a large group of pulmonary disorders characterized histologically by the cardinal involvement of the pulmonary interstitium. The prototype of ILDs is idiopathic pulmonary fibrosis (IPF), an incurable disease characterized by progressive distortion and loss of normal lung architecture through unchecked collagen deposition. Acute exacerbations are dramatic events during the clinical course of ILDs, associated with high morbidity and mortality. Infections, microaspiration, and advanced lung disease might be involved in the pathogenesis of acute exacerbations.

APA, Harvard, Vancouver, ISO, and other styles

5

Drakopanagiotakis, Fotios, Ekaterina Krauss, Ira Michailidou, et al. "Lung Cancer and Interstitial Lung Diseases." Cancers 16, no. 16 (2024): 2837. http://dx.doi.org/10.3390/cancers16162837.

Full text

Abstract:

Lung cancer continues to be one of the leading causes of cancer-related death worldwide. There is evidence of a complex interplay between lung cancer and interstitial lung disease (ILD), affecting disease progression, management strategies, and patient outcomes. Both conditions develop as the result of common risk factors such as smoking, environmental exposures, and genetic predispositions. The presence of ILD poses diagnostic and therapeutic challenges in lung cancer management, including difficulties in interpreting radiological findings and increased susceptibility to treatment-related tox

APA, Harvard, Vancouver, ISO, and other styles

6

Matsunashi, Atsushi, Kazuma Nagata, Takeshi Morimoto, and Keisuke Tomii. "Mechanical ventilation for acute exacerbation of fibrosing interstitial lung diseases." Respiratory Investigation 61, no. 3 (2023): 306–13. http://dx.doi.org/10.1016/j.resinv.2023.01.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Papanikolaou, Ilias C., Fotios Drakopanagiotakis, and Vlasis S. Polychronopoulos. "Acute exacerbations of interstitial lung diseases." Current Opinion in Pulmonary Medicine 16, no. 5 (2010): 480–86. http://dx.doi.org/10.1097/mcp.0b013e32833ae49d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Akulkina, L. A., M. Yu Brovko, A. A. Schepalina, et al. "A case of severe COVID-19 in a patient with progressive fibrosing interstitial lung disease." PULMONOLOGIYA 32, no. 5 (2022): 763–69. http://dx.doi.org/10.18093/0869-0189-2022-32-5-763-769.

Full text

Abstract:

Interstitial lung diseases (ILDs) is a wide group of diffuse parenchymal lung diseases that can lead to interstitial pulmonary fibrosis. Clinical course of all ILDs, in particular with chronic fibrosing phenotype, can be complicated by an acute exacerbation caused by infection. Today, data about clinical course of COVID-19 in patients with progressive interstitial lung diseases is limited. In this case we described the course of COVID-19 infection in a patient with an interstitial pneumonia with autoimmune features (IPAF) and a progressive pulmonary fibrosis (PPF). We also discussed the typica

APA, Harvard, Vancouver, ISO, and other styles

9

Magdy, Mohammed, Zainab Saaed, Emad Abd El-Aleem, and Madyan Mahmoud. "Clinical and radiological signs of acute exacerbation of interstitial lung diseases." Minia Journal of Medical Research 30, no. 3 (2019): 116–19. http://dx.doi.org/10.21608/mjmr.2022.221906.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Ito, Yoko, Gen Tazaki, Yusuke Kondo, Genki Takahashi, and Fumio Sakamaki. "Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases." Respiratory Medicine Case Reports 26 (2019): 317–20. http://dx.doi.org/10.1016/j.rmcr.2019.02.021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Suzuki, Atsushi, Yasuhiro Kondoh, Kevin K. Brown, et al. "Acute exacerbations of fibrotic interstitial lung diseases." Respirology 25, no. 5 (2019): 525–34. http://dx.doi.org/10.1111/resp.13682.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Amati, Francesco, Anna Stainer, Veronica Polelli, et al. "Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review." International Journal of Molecular Sciences 24, no. 9 (2023): 7849. http://dx.doi.org/10.3390/ijms24097849.

Full text

Abstract:

Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary fibrosis treatment by regulatory agencies and available for clinical use worldwide. These drugs have been shown to reduce the rate of decline in forced vital capacity and the risk of acute exacerbation among patients with idiopathic pulmonary fibrosis. Recent data suggest that different interstitial lung diseases with a progressive pulmonary fibrosis phenotype can share similar pathogenetic and biological pathways and could be amenable to antifibrotic therapies. Indeed, historical management strategies in

APA, Harvard, Vancouver, ISO, and other styles

13

On, Rintaro, Takemasa Matsumoto, Hisako Kushima, Ryosuke Hirano, and Masaki Fujita. "Prevalence of viral infection in acute exacerbation of interstitial lung diseases in Japan." Respiratory Investigation 58, no. 6 (2020): 473–78. http://dx.doi.org/10.1016/j.resinv.2020.06.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Salonen, Johanna, Minna Purokivi, Risto Bloigu, and Riitta Kaarteenaho. "Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases." BMJ Open Respiratory Research 7, no. 1 (2020): e000563. http://dx.doi.org/10.1136/bmjresp-2020-000563.

Full text

Abstract:

BackgroundThe aim of this study was to compare the clinical characteristics, causes of death and factors impacting on the prognosis of patients with idiopathic pulmonary fibrosis (IPF) and other fibrosing interstitial lung disease (FILD) with a history of acute exacerbation (AE) of IPF or FILD.MethodsRetrospective data of hospital treatment periods caused by AE-IPF and AE-FILD were collected from medical records. Clinical features and survival data of IPF and non-IPF cases were evaluated and compared. The underlying and immediate causes of death were gathered from death certificates.ResultsA t

APA, Harvard, Vancouver, ISO, and other styles

15

Enomoto, Noriyuki. "Pathological Roles of Pulmonary Cells in Acute Lung Injury: Lessons from Clinical Practice." International Journal of Molecular Sciences 23, no. 23 (2022): 15027. http://dx.doi.org/10.3390/ijms232315027.

Full text

Abstract:

Interstitial lung diseases (ILD) are relatively rare and sometimes become life threatening. In particular, rapidly progressive ILD, which frequently presents as acute lung injury (ALI) on lung histopathology, shows poor prognosis if proper and immediate treatments are not initiated. These devastating conditions include acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF), clinically amyopathic dermatomyositis (CADM), epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)-induced lung injury, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection named

APA, Harvard, Vancouver, ISO, and other styles

16

Kaarteenaho, Riitta, and Vuokko L. Kinnula. "Diffuse Alveolar Damage: A Common Phenomenon in Progressive Interstitial Lung Disorders." Pulmonary Medicine 2011 (2011): 1–10. http://dx.doi.org/10.1155/2011/531302.

Full text

Abstract:

It has become obvious that several interstitial lung diseases, and even viral lung infections, can progress rapidly, and exhibit similar features in their lung morphology. The final histopathological feature, common in these lung disorders, is diffuse alveolar damage (DAD). The histopathology of DAD is considered to represent end stage phenomenon in acutely behaving interstitial pneumonias, such as acute interstitial pneumonia (AIP) and acute exacerbations of idiopathic pulmonary fibrosis (IPF). Acute worsening and DAD may occur also in patients with nonspecific interstitial pneumonias (NSIPs)

APA, Harvard, Vancouver, ISO, and other styles

17

Sato, Toshihiko, Satoshi Teramukai, Haruhiko Kondo, et al. "Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer." Journal of Thoracic and Cardiovascular Surgery 147, no. 5 (2014): 1604–11. http://dx.doi.org/10.1016/j.jtcvs.2013.09.050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Austin, Adam, Johnny Jaber, Katherine Fu, et al. "Acute exacerbation of interstitial lung diseases and mortality post-cryobiopsy: a multicenter cohort study." Journal of Thoracic Disease 16, no. 7 (2024): 4340–49. http://dx.doi.org/10.21037/jtd-24-270.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Furukawa, Hiroshi, Shomi Oka, Kota Shimada, et al. "Role of Deleterious Rare Alleles for Acute-Onset Diffuse Interstitial Lung Disease in Collagen Diseases." Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 13 (January 2019): 117954841986644. http://dx.doi.org/10.1177/1179548419866443.

Full text

Abstract:

Objective: Acute-onset diffuse interstitial lung disease (AoDILD) includes acute exacerbation of interstitial lung disease (ILD), drug-induced ILD, and Pneumocystis pneumonia in collagen diseases patients. As AoDILD causes a poor prognosis in collagen disease patients, the pathogenesis of AoDILD should be investigated. Exome sequencing studies revealed that rare variants were detected to be causative in some diseases. Recently reported upregulated genes in acute exacerbation of idiopathic pulmonary fibrosis could provide candidate genes for restricted exome analysis of AoDILD in collagen disea

APA, Harvard, Vancouver, ISO, and other styles

20

Larsen, Brandon T., and Thomas V. Colby. "Update for Pathologists on Idiopathic Interstitial Pneumonias." Archives of Pathology & Laboratory Medicine 136, no. 10 (2012): 1234–41. http://dx.doi.org/10.5858/arpa.2012-0225-ra.

Full text

Abstract:

Context.—Idiopathic interstitial pneumonias are a subset of diffuse pulmonary interstitial diseases classified by international consensus in 2002 as idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, acute interstitial pneumonia, respiratory bronchiolitis interstitial lung disease, desquamative interstitial pneumonia, and lymphoid interstitial pneumonia. Each is associated with a characteristic histopathologic pattern. In 2011, updated consensus guidelines were released for diagnosis and management of idiopathic pulmonary fibrosis. The entire g

APA, Harvard, Vancouver, ISO, and other styles

21

Faverio, Paola, Anna Stainer, Sara Conti, et al. "Differences between Acute Exacerbations of Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases." Diagnostics 11, no. 9 (2021): 1623. http://dx.doi.org/10.3390/diagnostics11091623.

Full text

Abstract:

Interstitial lung diseases (ILDs) comprise a wide group of pulmonary parenchymal disorders. These patients may experience acute respiratory deteriorations of their respiratory condition, termed “acute exacerbation” (AE). The incidence of AE-ILD seems to be lower than idiopathic pulmonary fibrosis (IPF), but prognosis and prognostic factors are largely unrecognized. We retrospectively analyzed a cohort of 158 consecutive adult patients hospitalized for AE-ILD in two Italian university hospitals from 2009 to 2016. Patients included in the analysis were divided into two groups: non-IPF (62%) and

APA, Harvard, Vancouver, ISO, and other styles

22

Kimura, Toru, T. Nojiri, H. Hosoda, et al. "P-227ESTABLISHMENT OF A NEW MOUSE MODEL FOR POSTOPERATIVE ACUTE EXACERBATION OF INTERSTITIAL LUNG DISEASES." Interactive CardioVascular and Thoracic Surgery 21, suppl_1 (2015): S62. http://dx.doi.org/10.1093/icvts/ivv204.227.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Saraya, Takeshi, Hirokazu Kimura, Daisuke Kurai, et al. "Clinical significance of respiratory virus detection in patients with acute exacerbation of interstitial lung diseases." Respiratory Medicine 136 (March 2018): 88–92. http://dx.doi.org/10.1016/j.rmed.2018.02.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Salonen, Johanna, Hannu Vähänikkilä, Minna Purokivi, and Riitta Kaarteenaho. "Causes of acute respiratory hospitalizations predict survival in fibrosing interstitial lung diseases." PLOS ONE 15, no. 11 (2020): e0242860. http://dx.doi.org/10.1371/journal.pone.0242860.

Full text

Abstract:

Acute exacerbation of ILD (AE-ILD) is a common reason for hospitalization; it is also associated with significant mortality. Less is known about the prognostic significance of other events causing acute, non-elective hospitalizations in ILD patients. ILD patients hospitalized due to acute respiratory worsening were collected from medical records. Reasons for respiratory deterioration were classified into AE-ILDs and other causes. Clinical features and survival data of idiopathic pulmonary fibrosis (IPF) and other types of ILDs were evaluated and compared. In all, 237 patients (138 with IPF and

APA, Harvard, Vancouver, ISO, and other styles

25

Banuls, Lorrain, Juliette Vanoverschelde, Fanny Garnier, et al. "Interstitial Lung Disease Worsens Short- and Long-Term Outcomes of Systemic Rheumatic Disease Patients Admitted to the ICU: A Multicenter Study." Journal of Clinical Medicine 10, no. 5 (2021): 1037. http://dx.doi.org/10.3390/jcm10051037.

Full text

Abstract:

Critically ill patients with systemic rheumatic diseases (SRDs) have a fair prognosis, while those with interstitial lung disease (ILD) have a poorer outcome. However, the prognosis of SRD patients with ILD admitted to the intensive care unit (ICU) remains unclear. We conducted a case–control study to investigate the outcomes of critically ill SRD-ILD patients. Consecutive SRD-ILD patients admitted to five ICUs from January 2007 to December 2017 were compared to SRD patients without ILD. Mortality rates were compared between groups, and prognostic factors were then identified. One hundred and

APA, Harvard, Vancouver, ISO, and other styles

26

von der Beck, Daniel, Friedrich Grimminger, Werner Seeger, Andreas Günther, and Benjamin Löh. "Interstitial Lung Disease: Seasonality of Hospitalizations and In-Hospital Mortality 2005–2015." Respiration 101, no. 3 (2021): 253–61. http://dx.doi.org/10.1159/000519214.

Full text

Abstract:

<b><i>Background:</i></b> The overall incidence of interstitial lung disease and disease-associated mortality have been found on the rise. Hospitalizations for interstitial lung disease are typically caused by airway infection or the acute exacerbation of the underlying disease. Seasonal variance in ambient air pollution has recently been linked to exacerbation and mortality. We sought to examine the seasonal pattern of hospitalizations in Germany, use of mechanical ventilation, and in-hospital mortality on a year-by-year basis to identify their overall trend and to cha

APA, Harvard, Vancouver, ISO, and other styles

27

Anwar, Khadeeja, Ummara Siddique, Irfanullah Khan, et al. "Diagnostic Accuracy of Chest X-Ray in Interstitial Lung Diseases, Keeping High Resolution Computed Tomography Scan as Gold Standard." Journal of Gandhara Medical and Dental Science 11, no. 1 (2023): 64–67. http://dx.doi.org/10.37762/jgmds.11-1.559.

Full text

Abstract:

OBJECTIVES To determine the accuracy of the plain chest radiograph in diagnosing interstitial lung diseases (ILDs), keeping a high-resolution CT scan (HRCT) as the gold standard. METHODOLOGY A cross-sectional study was conducted. A total of 75 patients who visited the Department of Radiology department over two years were assessed by prospective analysis of their radiology reports. All the HRCTs and Chest X-ray images were reviewed. Data collected was recorded on a specially designed proforma and entered into Microsoft Excel and SPSS (Version 22.0. IBM Corp., Armonk, NY). Patients with a histo

APA, Harvard, Vancouver, ISO, and other styles

28

Suda, Takafumi. "Up-to-Date Information on Rheumatoid Arthritis-Associated Interstitial Lung Disease." Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 9s1 (January 2015): CCRPM.S23289. http://dx.doi.org/10.4137/ccrpm.s23289.

Full text

Abstract:

Pulmonary involvement is common in rheumatoid arthritis (RA) and affects all the components of the lung. Interstitial lung disease (ILD) is the most predominant pulmonary manifestation and has been identified as the main cause of morbidity and mortality in RA. Clinically significant RA-ILD occurs in approximately 10% of RA patients. Several risk factors, such as old age, male gender, and smoking, have been reported to date. Histologically, the proportion of the usual interstitial pneumonia (UIP) pattern is higher in RA-ILD than in ILD associated with other connective tissue diseases, and RA-IL

APA, Harvard, Vancouver, ISO, and other styles

29

Izuka, S., H. Yamashita, Y. Takahashi, and H. Kaneko. "SAT0040 RISK FACTORS FOR DEVELOPING AND MORTALITY FOR ACUTE EXACERBATION OF RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 950.2–951. http://dx.doi.org/10.1136/annrheumdis-2020-eular.411.

Full text

Abstract:

Background:Among collagen vascular diseases, rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is the most commonly associated with ILD with acute exacerbation (AE) [1]. One study reported that ILD diagnosis at an older age, the usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography, and methotrexate (MTX) use were associated with AE in patients with RA-ILD [2]. However, because these studies included few patients, the risk factors and prognosis of AE in patients with RA-ILD remain unclear. Therefore, this study examined the characteristics of RA-ILD

APA, Harvard, Vancouver, ISO, and other styles

30

Kershaw, Corey D., Kiran Batra, Jose R. Torrealba, and Lance S. Terada. "Characteristics and evaluation of acute exacerbations in chronic interstitial lung diseases." Respiratory Medicine 183 (July 2021): 106400. http://dx.doi.org/10.1016/j.rmed.2021.106400.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Yasuda, Yuto, Takashi Nomizo, Hiroaki Ozasa, et al. "Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease." Molecular and Clinical Oncology 7, no. 4 (2017): 677–80. http://dx.doi.org/10.3892/mco.2017.1373.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Cano-Jiménez, Esteban, Fernanda Hernández González, and Guadalupe Peloche. "Comorbidities and Complications in Idiopathic Pulmonary Fibrosis." Medical Sciences 6, no. 3 (2018): 71. http://dx.doi.org/10.3390/medsci6030071.

Full text

Abstract:

Though idiopathic pulmonary fibrosis (IPF) is characterized by single-organ involvement, many comorbid conditions occur within other organ systems. Patients with IPF may present during evolution different complications and comorbidities that influence the prognosis and modify the natural course of their disease. In this chapter, we highlight common comorbid conditions encountered in IPF, discuss disease-specific diagnostic modalities, and review the current treatment data for several key comorbidities. The diagnosis and treatment of these comorbidities is a challenge for the pulmonologist spec

APA, Harvard, Vancouver, ISO, and other styles

33

Manfredi, Andreina, Marco Sebastiani, Stefania Cerri, et al. "Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature." Journal of Thoracic Disease 11, no. 4 (2019): 1621–28. http://dx.doi.org/10.21037/jtd.2019.03.28.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Korolev, A. M. "Blood changes in chronic nonspecific lung diseases under the influence of hemotherapy." Kazan medical journal 50, no. 4 (2022): 67. http://dx.doi.org/10.17816/kazmj101353.

Full text

Abstract:

We observed 50 patients aged 15 to 70 years. There were 15 people with prolonged acute pneumonia, 15 with bronchial asthma, 11 with chronic interstitial pneumonia, 9 with pneumosclerosis. There were 23 men, 27 women. Patients with chronic interstitial pneumonia also suffered from bronchiectasis, often multiple, with periodic exacerbations. Bronchial asthma in 15 people was accompanied by severe attacks in recent years, in a number of patients it was complicated by pneumosclerosis in the stage of emphysema and bronchiectasis.

APA, Harvard, Vancouver, ISO, and other styles

35

Kimura, Toru, Takashi Nojiri, Hiroshi Hosoda, et al. "Exacerbation of bleomycin-induced injury by lipopolysaccharide in mice: establishment of a mouse model for acute exacerbation of interstitial lung diseases." European Journal of Cardio-Thoracic Surgery 48, no. 4 (2015): e85-e91. http://dx.doi.org/10.1093/ejcts/ezv261.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Lee, Jae Ha, Ji Hoon Jang, Jin Han Park, et al. "The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases." PLOS ONE 16, no. 7 (2021): e0255365. http://dx.doi.org/10.1371/journal.pone.0255365.

Full text

Abstract:

Background Interstitial lung diseases (ILDs) are chronic, parenchymal lung diseases with a variable clinical course and a poor prognosis. Within various clinical courses, acute exacerbation (AE) is a devastating condition with significant morbidity and high mortality. The aim of this study was to investigate the role of interleukin-6 (IL-6) to predict AE and prognosis in patients with ILD. Methods Eighty-three patients who were diagnosed with ILD from 2016 to 2019 at the Haeundae Paik Hospital, Busan, South Korea, were included and their clinical data were retrospectively analyzed. Results The

APA, Harvard, Vancouver, ISO, and other styles

37

Beghé, Bianca, Stefania Cerri, Leonardo M. Fabbri, and Alessandro Marchioni. "COPD, Pulmonary Fibrosis and ILAs in Aging Smokers: The Paradox of Striking Different Responses to the Major Risk Factors." International Journal of Molecular Sciences 22, no. 17 (2021): 9292. http://dx.doi.org/10.3390/ijms22179292.

Full text

Abstract:

Aging and smoking are associated with the progressive development of three main pulmonary diseases: chronic obstructive pulmonary disease (COPD), interstitial lung abnormalities (ILAs), and idiopathic pulmonary fibrosis (IPF). All three manifest mainly after the age of 60 years, but with different natural histories and prevalence: COPD prevalence increases with age to >40%, ILA prevalence is 8%, and IPF, a rare disease, is 0.0005–0.002%. While COPD and ILAs may be associated with gradual progression and mortality, the natural history of IPF remains obscure, with a worse prognosis and life e

APA, Harvard, Vancouver, ISO, and other styles

38

Yamakawa, Hideaki, Takashi Ogura, Hideto Kameda, et al. "Decision-Making Strategy for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD)." Journal of Clinical Medicine 10, no. 17 (2021): 3806. http://dx.doi.org/10.3390/jcm10173806.

Full text

Abstract:

Rheumatoid arthritis (RA) is a common type of autoimmune arthritis. Patient clinical outcomes might be influenced by numerous respiratory diseases, but interstitial lung disease (ILD) is the most important comorbidity. RA-associated ILD (RA-ILD) is divided into acute/subacute and chronic forms. In the acute/subacute course, if the disease is severe as indicated by a diffuse alveolar damage pattern, high-dose corticosteroids combined with antimicrobial agents should be promptly initiated while considering the differential diagnoses, primarily acute exacerbation (AE) of RA-ILD, drug-induced pneu

APA, Harvard, Vancouver, ISO, and other styles

39

Ricci, Alberto, Alessandra Pagliuca, Morgana Vermi, et al. "The Role of Lung Colonization in Connective Tissue Disease-Associated Interstitial Lung Disease." Microorganisms 9, no. 5 (2021): 932. http://dx.doi.org/10.3390/microorganisms9050932.

Full text

Abstract:

Connective tissue diseases (CTDs) may frequently manifest with interstitial lung disease (ILD), which may severely impair quality and expectation of life. CTD-ILD generally has a chronic clinical course, with possible acute exacerbations. Although several lines of evidence indicate a relevant role of infections in the acute exacerbations of CTD-ILD, little information is available regarding the prevalence of infections in chronic CTD-ILD and their possible role in the clinical course. The aim of the present retrospective study was the identification of lung microbial colonization in broncho-al

APA, Harvard, Vancouver, ISO, and other styles

40

Nakashima, Kazuki, Toyoshi Yanagihara, Sae Ishida, et al. "Three cases of sequential treatment with nintedanib following pulsed-dose corticosteroids for acute exacerbation of interstitial lung diseases." Respiratory Medicine Case Reports 33 (2021): 101385. http://dx.doi.org/10.1016/j.rmcr.2021.101385.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Manfredi, Andreina, Marco Sebastiani, Stefania Cerri, et al. "Erratum to acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature." Journal of Thoracic Disease 12, no. 10 (2020): 6411. http://dx.doi.org/10.21037/jtd-2020-64.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Clement, Annick, Jacques de Blic, Ralph Epaud, et al. "Management of children with interstitial lung diseases: the difficult issue of acute exacerbations." European Respiratory Journal 48, no. 6 (2016): 1559–63. http://dx.doi.org/10.1183/13993003.01900-2016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Rodrigues, Inês, Ricardo Estêvão Gomes, Lígia Maria Coutinho, et al. "Diagnostic yield and safety of transbronchial lung cryobiopsy and surgical lung biopsy in interstitial lung diseases: a systematic review and meta-analysis." European Respiratory Review 31, no. 166 (2022): 210280. http://dx.doi.org/10.1183/16000617.0280-2021.

Full text

Abstract:

Introduction:Transbronchial lung cryobiopsy (TBLC) is increasingly being used as an alternative to video-assisted thoracoscopic surgery (VATS) biopsy to establish the histopathologic pattern in interstitial lung disease (ILD).Methods:A systematic literature search of the PubMed and Embase databases, from October 2010 to October 2020, was conducted to identify studies that reported on diagnostic yield or safety of VATS or TBLC in the diagnosis of ILD.Results:43 studies were included. 23 evaluated the diagnostic yield of TBLC after multidisciplinary discussion, with a pooled diagnostic yield of

APA, Harvard, Vancouver, ISO, and other styles

44

Araujo, Mariana Sponholz, Frederico Leon Arrabal Fernandes, Fernando Uliana Kay, and Carlos Roberto Ribeiro Carvalho. "Pneumomediastinum, subcutaneous emphysema, and pneumothorax after a pulmonary function testing in a patient with bleomycin-induced interstitial pneumonitis." Jornal Brasileiro de Pneumologia 39, no. 5 (2013): 613–19. http://dx.doi.org/10.1590/s1806-37132013000500012.

Full text

Abstract:

Spontaneous pneumomediastinum is an uncommon event, the clinical picture of which includes retrosternal chest pain, subcutaneous emphysema, dyspnea, and dysphonia. The pathophysiological mechanism involved is the emergence of a pressure gradient between the alveoli and surrounding structures, causing alveolar rupture with subsequent dissection of the peribronchovascular sheath and infiltration of the mediastinum and subcutaneous tissue with air. Known triggers include acute exacerbations of asthma and situations that require the Valsalva maneuver. We described and documented with HRCT scans th

APA, Harvard, Vancouver, ISO, and other styles

45

Inotani, S., Y. Kondo, S. Takanashi, et al. "POS1220 TRANSITION IN SYMPTOMS, ORGAN INVOLVEMENT, AND CLINICAL DIAGNOSIS OF PATIENTS POSITIVE FOR ANTI-ARS ANTIBODIES." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 945.1–945. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1345.

Full text

Abstract:

BackgroundMyositis-specific autoantibodies are useful biomarkers to make a diagnosis and predict prognosis of idiopathic inflammatory myopathies. Anti-aminoacyl transfer RNA synthetase antibodies (anti-ARS) is one of the most representative myositis-specific autoantibodies, however, organ involvement in patients positive for anti-ARS is not limited to the muscles but also skin, joints, and lungs, which constructs spectrums of idiopathic inflammatory myopathies called anti-synthetase syndrome. While individual anti-ARS antibodies have been known to form distinct clinical subsets, little is know

APA, Harvard, Vancouver, ISO, and other styles

46

van den Bosch, Laura, Fabrizio Luppi, Giovanni Ferrara, and Marco Mura. "Immunomodulatory treatment of interstitial lung disease." Therapeutic Advances in Respiratory Disease 16 (January 2022): 175346662211170. http://dx.doi.org/10.1177/17534666221117002.

Full text

Abstract:

Interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) have an array of immunomodulatory treatment options compared with IPF, due to their inflammatory component. However, there is a relative paucity of guidance on the management of this heterogeneous group of diseases. In ILDs other than IPF, immunosuppression is the cornerstone of therapy, with varying levels of evidence for different immunomodulatory agents and for each specific ILD. Classification of ILDs is important for guiding treatment decisions. Immunomodulatory agents mainly include corticosteroids, mycophen

APA, Harvard, Vancouver, ISO, and other styles

47

Tandjaoui-Lambiotte, Y., F. Gonzalez, M. Boubaya, et al. "Two-year follow-up of 196 interstitial lung disease patients after ICU stay." International Journal of Tuberculosis and Lung Disease 25, no. 3 (2021): 199–205. http://dx.doi.org/10.5588/ijtld.20.0706.

Full text

Abstract:

OBJECTIVE: Interstitial lung diseases (ILDs) are associated with poor prognosis in the intensive care unit (ICU). We aimed to assess factors associated with hospital mortality in ILD patients admitted to the ICU and to investigate long-term outcome.MATERIAL AND METHODS: This was a retrospective study in a teaching hospital specialised in ILD management. Patients with ILD who were hospitalised in the ICU between 2000 and 2014 were included. Independent predictors of hospital mortality were identified using logistic regression.RESULTS: A total of 196 ILD patients were admitted to the ICU during

APA, Harvard, Vancouver, ISO, and other styles

48

Laneri, Alessia, Stefania Cerri, Giovanni Della Casa, et al. "COVID-19, A New Possible Mimicker of Interstitial Lung Disease Related to Primary Sjögren’s Syndrome." Case Reports in Medicine 2023 (December 9, 2023): 1–6. http://dx.doi.org/10.1155/2023/9915553.

Full text

Abstract:

Introduction. Acute exacerbation of interstitial lung disease (ILD) and COVID-19 pneumonia show many similarities, but also COVID-19 sequelae, mainly when fibrotic features are present, can be difficult to distinguish from chronic ILD observed in connective tissue diseases. Case Report. In 2018, a 52-year-old woman, was diagnosed with primary Sjogren’s syndrome (pSS). The patient did not show respiratory symptoms, and a chest X-ray was normal. During March 2020, the patient was hospitalized for acute respiratory failure related to COVID-19 pneumonia. Three months later, follow-up chest high-re

APA, Harvard, Vancouver, ISO, and other styles

49

Han, Ji-yeon, and Jae Ha Lee. "Application and Interpretation of High-Resolution Computed Tomography for the Diagnosis of Interstitial Lung Disease (ILD): ILD Protocol." Korean Journal of Medicine 98, no. 6 (2023): 294–99. http://dx.doi.org/10.3904/kjm.2023.98.6.294.

Full text

Abstract:

Interstitial lung disease (ILD) encompasses a heterogeneous group of over 200 diffuse parenchymal lung diseases. Accurate diagnosis of ILD is essential for appropriate treatment but can be challenging to achieve. For patients with suspected ILD, high-resolution computed tomography (HRCT) is a minimally invasive approach that allows for convenient repeat imaging. Compared to a conventional computed tomography (CT) protocol, the HRCT protocol for ILD patients involves two additional series with different technical requirements: a prone inspiration scan, and a supine expiration scan. The prone sc

APA, Harvard, Vancouver, ISO, and other styles

50

Sharma, Neha, Chandran Nagaraj, Bence M. Nagy, et al. "RGS5 Determines Neutrophil Migration in the Acute Inflammatory Phase of Bleomycin-Induced Lung Injury." International Journal of Molecular Sciences 22, no. 17 (2021): 9342. http://dx.doi.org/10.3390/ijms22179342.

Full text

Abstract:

The regulator of G protein signaling (RGS) represents a widespread system of controllers of cellular responses. The activities of the R4 subfamily of RGSs have been elucidated in allergic pulmonary diseases. However, the R4 signaling in other inflammatory lung diseases, with a strong cellular immune response, remained unexplored. Thus, our study aimed to discern the functional relevance of the R4 family member, RGS5, as a potential modulating element in this context. Gene profiling of the R4 subfamily showed increased RGS5 expression in human fibrosing lung disease samples. In line with this,

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!